Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01302834 · OUTCOME

Number of Participants by HHIA-S Category at 12 Months After End of Treatment

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer · Source last updated 2026-07-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
12 months after end of treatment. Treatment lasts 6-7 weeks.

What was measured

The HHIA-S measures a person's perceived hearing handicap. Total score ranges from 0 to 40, with a higher score indicating more severe perceived hearing handicap, categorized as follows: * No handicap: 0-8. * Mild-moderate handicap: 10-24. * Severe handicap: 26-40.

Analysis population: Eligible participants enrolled to the quality of life (QOL) substudy who received protocol treatment and had outcome measure data.

Groups in this outcome

IMRT + Cisplatin

Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin Cisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT IMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.

IMRT + Cetuximab

Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab Cetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks IMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
IMRT + Cisplatin121
IMRT + Cetuximab125

Reported measurements

Source class 1

No handicap

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin84Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab103Not reportedNot reportedNot reportedNot reported

Mild-moderate handicap

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin27Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab17Not reportedNot reportedNot reportedNot reported

Severe handicap

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin10Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        84
      2. group Id
        OG001
        value
        103
      title
      No handicap
    2. measurements
      1. group Id
        OG000
        value
        27
      2. group Id
        OG001
        value
        17
      title
      Mild-moderate handicap
    3. measurements
      1. group Id
        OG000
        value
        10
      2. group Id
        OG001
        value
        5
      title
      Severe handicap
denoms
  1. counts
    1. group Id
      OG000
      value
      121
    2. group Id
      OG001
      value
      125
    units
    Participants
description
The HHIA-S measures a person's perceived hearing handicap. Total score ranges from 0 to 40, with a higher score indicating more severe perceived hearing handicap, categorized as follows: * No handicap: 0-8. * Mild-moderate handicap: 10-24. * Severe handicap: 26-40.
groups
  1. description
    Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin Cisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT IMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
    id
    OG000
    title
    IMRT + Cisplatin
  2. description
    Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab Cetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks IMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
    id
    OG001
    title
    IMRT + Cetuximab
param Type
COUNT_OF_PARTICIPANTS
population Description
Eligible participants enrolled to the quality of life (QOL) substudy who received protocol treatment and had outcome measure data.
reporting Status
POSTED
time Frame
12 months after end of treatment. Treatment lasts 6-7 weeks.
title
Number of Participants by HHIA-S Category at 12 Months After End of Treatment
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice